Remegen (09995) announced that on January 12, 2026, the company entered into an exclusive licensing agreement with AbbVie for RC148, which took effect on March 10, 2026. Under the agreement, AbbVie will obtain exclusive rights to develop, manufacture, and commercialize RC148 outside Greater China. In return, Remegen will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in additional development, regulatory, and commercial milestone payments, as well as tiered double-digit royalties on net sales outside Greater China. The board of directors is pleased to announce that the company has received the $650 million upfront payment from AbbVie (through its holding company) for the exclusive licensing agreement of RC148, a novel self-developed PD-1/VEGF bispecific antibody drug. The collaboration between the two parties is currently progressing smoothly.